AstraZeneca presented new data underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...
AstraZeneca and Bristol-Myers Squibb Company announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for...
In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes
The FDA has issued a Complete Response Letter regarding the New Drug Application for investigational compound dapagliflozin from BMS/AstraZeneca for...
AstraZeneca and BMS announced results from a Phase III study evaluating dapagliflozin (Forxiga in EU) in adult patients with Type...
AstraZeneca has announced results from a Phase III study evaluating the investigational combination of saxagliptin/dapagliflozin as a dual add-on therapy...
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73m2.
Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to kidney failure.
The National Institute for Health and Care Excellence (NICE) has recommended Forxiga (dapagliflozin) from AstraZeneca as part of a triple...
These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.